effect overlay
activetrials
Movement Disorders
Movement Disorders
GAIN GNX

An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Participants with Parkinson’s Disease With or Without a Pathogenic GBA1 Mutation

HREC: 2025.016
Principal Investigator: Dr Andrew Evans
Coordinator contact: Reena Chopra
Funding: Commercial
Epilepsy
Epilepsy
Xenon 302

A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures (XTOLE3)

HREC: 2025.006
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Karen Chidgey
Funding: Commercial
Active Trials - Other
Neurophysiology
EMPASSION

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy

HREC: 2025.002
Principal Investigator: Dr Belinda Cruse
Coordinator contact: Kate Furlong
Funding: Commercial
Stroke
Stroke
CervoMed

A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery after Moderate to Severe Acute Ischaemic Stroke

HREC: 2024.318
Principal Investigator: Prof Bruce Campbell
Coordinator contact:
Funding: Commercial
Epilepsy
Epilepsy
PERSONAL: AI for Epilepsy

PERsonalised Selection Of medication for Newly diagnosed Adult epiLepsy - the PERSONAL Trial

HREC: 2024.164
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Sean Hosking
Funding: Commercial